Table 1.
Clinical characteristics of patients with advanced EGFR-mutated LADC transforming to SCLC.
| Characteristics | Total (n = 72) | ttSCLC (95% CI) | T-ttSCLC (95% CI) |
|---|---|---|---|
| Age | |||
| Median (range) | 56.5 years (31–76 years) | 20.5 m (3–75 m) | 18.5 m (3–64 m) |
| Gender (%) | |||
| Male | 22 (30.6%) | 14.0m (14.58–26.07 m) | 14.0 m (13.48–23.72 m) |
| Female | 50 (69.4%) | 21.5 m (22.00–30.88 m) | 19.5 m (18.91–26.28 m) |
| Race (%) | |||
| Asian | 21 (70.8%) | 22.0 m (18.44–31.8 m) | 19.0 m (16.47–28.10 m) |
| White | 51 (29.2%) | 20.0 m (20.03–28.64 m) | 17.0 m (17.45–24.56 m) |
| Smoking (%) | n = 64 | ||
| Never smoking | 19 (29.7%) | 20.0 m (21.12–31.02 m) | 18.0 m (17.65–25.55 m) |
| Ever smoking | 45 (70.3%) | 20 m (14.68–23.63 m) | 20 m (13.75–2.51 m) |
| TNM stage | |||
| II | 4 (5.5%) | 44.5 m (10.20–72.80 m) | 18.0 m (5.62–37.38 m) |
| III | 7 (9.7%) | 29.0 m (18.05–38.67 m) | 23.0 m (15.36–26.72 m) |
| IV | 61 (84.7%) | 20.0 m (19.23–27.71 m) | 18.0 m (18.17–25.05 m) |
| Founder EGFR mutation (%) | |||
| 19-del | 54 (75.0%) | 21.0 m (20.78–29.29 m) | 19.0 m (18.13–25.11 m) |
| 21-L858R | 16 (22.2%) | 20.0 m (16.93–31.20 m) | 20.0 m (14.59–28.35 m) |
| 18-G719X | 2 (2.8%) | 14.0 m | 14.0 m |
| First line TKIs type using (%) | |||
| Gefitinib | 33 (45.8%) | 20.0 m (19.38–30.57 m) | 17.0 m (16.41–26.33) |
| Erlotinib | 24 (33.3%) | 22.0 m (19.60–32.24 m) | 20.0 m (17.56–26.19) |
| Afatinib | 9 (12.5%) | 19.0 m (10.17–34.94 m) | 18.0 m (9.12–32.88) |
| Icotinib | 4 (5.5%) | 16.0 m | 16.0 m |
| Osimertinib | 2 (2.7%) | 18.0 m | 18.0 m |
m, months; TKIs, Tyrosine kinase inhibitors; 19del, EGFR exon 19-deletion; 21 L858R, EGFR exon 21-L858R; 18-G719X, EGFR exon 18-G719X; TNM stage, the stage at the time of diagnosis; ttSCLC, the time from the initial pathological diagnosis of LADC to the additional biopsy revealing the metachronous SCLC phenotype; T-ttSCLC, the time from the initial TKIs usage to the additional biopsy revealing the metachronous SCLC phenotype.